148672-43-9 Usage
General Description
4-Bromo-3-Methylbenzhydrazide is a chemical compound that belongs to the category of organic compounds known as aniline and substituted anilines. These are organic compounds containing an aminobenzene moiety. It appears as a solid and is potentially safe to handle when following standard chemical safety measures. 4-BROMO-3-METHYLBENZHYDRAZIDE can be used in various scientific research and laboratory experiments which includes its role in the synthesis of other important chemicals or compounds. However, detailed information about its physical and chemical properties like molecular weight, density, melting and boiling point are needed for its proper application. No information is available about its toxicity or environmental impact, therefore caution should be exercised during its usage.
Check Digit Verification of cas no
The CAS Registry Mumber 148672-43-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,8,6,7 and 2 respectively; the second part has 2 digits, 4 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 148672-43:
(8*1)+(7*4)+(6*8)+(5*6)+(4*7)+(3*2)+(2*4)+(1*3)=159
159 % 10 = 9
So 148672-43-9 is a valid CAS Registry Number.
InChI:InChI=1/C8H9BrN2O/c1-5-4-6(8(12)11-10)2-3-7(5)9/h2-4H,10H2,1H3,(H,11,12)
148672-43-9Relevant articles and documents
AROMATIC RING OR HETEROAROMATIC RING COMPOUNDS, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF
-
Paragraph 0094; 0098; 0175; 0177, (2021/12/18)
The present invention relates to aromatic ring or heteroaromatic ring compounds, a preparation method therefor and a medical use thereof. Particularly, the present invention relates to a compound as shown in general formula (I) and a preparation method th
NOVEL COMPOUNDS
-
Paragraph 0330; 0331; 0332, (2013/07/25)
This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.